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Background and Purpose—A high degree of proteinuria has been reported in stroke-prone spontaneously hypertensive rats
(SHRSP). We studied the effect of salt loading on the detailed protein pattern of serum and urine in 3 rat strains:
Wistar-Kyoto, spontaneously hypertensive rats, and SHRSP, an inbred animal model for a complex form of
cerebrovascular disorder resembling the human disease.
Methods—Rats were given a permissive diet and received 1% NaCl in drinking water. The protein pattern in body fluids
was assessed over time by 2-dimensional electrophoretic analysis. Brain alterations were monitored by MRI and
histology.
Results—Several proteins were excreted in urine after weeks of treatment and in advance of stroke: transferrin, hemopexin,
albumin, a2-HS-glycoprotein, kallikrein-binding protein, a1-antitrypsin, Gc-globulin, and transthyretin. Markers of an
inflammatory response, including very high levels of thiostatin, were detected in the serum of SHRSP at least 4 weeks
before a stroke occurred.
Conclusions—In SHRSP subjected to salt loading, an atypical inflammatory condition and widespread alterations of
vascular permeability developed before the appearance of anomalous features in the brain detected by MRI. Urinary
concentrations of each of the excreted serum proteins correlated positively with time before stroke occurred. (Stroke.
2001;32:753-760.)
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The spontaneously hypertensive stroke-prone rat (SHRSP)provides an inbred animal model for a complex form of
cerebrovascular pathology resembling, in many aspects, the
human disease.1 In these animals stroke occurs only after high
blood pressure has developed; lag time is greatly reduced if
rats are exposed to a specific permissive diet, low in potas-
sium and protein and high in sodium (Japanese permissive
diet [JPD]).2 In this model, stroke is not just a consequence of
long-standing hypertension but represents the final outcome
of a complex interaction between environmental (ie, dietary)
and genetic factors.3 The role of the latter is emphasized by
the resistance to stroke of a closely related strain, the
spontaneously hypertensive rat (SHR), which remains stroke-
free despite a similar degree of hypertension after exposure to
JPD.
Recent data show that alterations in structure, regulation,
and function of the gene encoding atrial natriuretic peptide
(ANP) are significantly linked to cerebral disease in SHRSP.4
Further reports suggest that molecular variants of the ANP
gene represent an independent risk factor for human stroke.5
These data confirm the resemblance between cerebrovascular
accidents in humans and in the SHRSP model.
It has been shown that cerebral edema identified by
T2-weighted MRI in salt-loaded SHRSP is preceded by
proteinuria.6 Preliminary experiments performed on urine
samples of SHRSP showed that, in addition to albumin,
several acute-phase proteins are detectable by means of
2-dimensional electrophoresis. This observation suggested to
us that in this animal model inflammation might occur well
before the onset of the acute cerebral event. Therefore, this
study addressed the issue of a potential contribution of acute
inflammation to the occurrence of cerebral damage in salt-
loaded SHRSP.
The term proteome refers to proteins expressed by a
genome in a given tissue at a given time; its analysis relies on
2-dimensional polyacrylamide gel electrophoresis. The si-
multaneous characterization and quantification in body fluids
of gene products and of their posttranslational modifications
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can suggest which biochemical mechanisms are involved in a
pathological situation and may identify disease markers.7,8
Our group has extensively studied the proteome of rat serum,
identifying and quantifying all major proteins under baseline
conditions and after a number of experimental treatments.9–14
In this report the proteome of serum and urine in SHRSP
rats exposed to JPD during and after the development of
cerebral damage, in comparison with SHR and Wistar-Kyoto
rats (WKY), was characterized by 2-dimensional polyacryl-
amide gel electrophoresis.
Materials and Methods
Animals and Treatments
Procedures involving animals and their care were conducted at
Dipartimento di Scienze Farmacologiche dell’Università degli Studi
di Milano in conformity with the institution’s guidelines, which are
in compliance with national (D.L. No. 116, G.U., suppl. 40, February
18, 1992, Circolare No. 8, G.U., July 14, 1994) and international
(EEC Council Directive 86/609, OJL 358, 1, December 12, 1987;
Guide for the Care and Use of Laboratory Animals, US National
Research Council, 1996) rules and policies.
Male WKY (n55), SHR (n55), and SHRSP (n58) were pur-
chased from Charles River. At 6 weeks of age the animals were
placed on JPD (Laboratorio Dr Piccioni; 18.7% protein, 0.63%
potassium, 0.37% sodium) and received 1% NaCl in drinking water.
Animal treatment lasted up to 49 days. The body weight of the
animals, as well as food and liquid intake, was recorded weekly.
Serum and 24-hour urine were sampled and arterial blood pressure
was monitored before the onset of the diet and every seventh day
afterward. Systolic arterial blood pressure was measured in con-
scious rats by tail-cuff plethysmography (PB Recorder 8006, Ugo
Basile), after warming at 37°C.
Blood was drawn from the tail vein at different time intervals (see
Results), and serum was obtained by allowing the blood to clot for 1
hour at 37°C followed by centrifugation for 20 minutes at 3000 rpm.
Urine was collected by housing rats in individual metabolic cages; its
protein concentration was measured according to Bradford15 with
bovine albumin as standard.
All rats underwent weekly MRI. MRI assessment was repeated
every other day in SHRSP once 24-hour proteinuria exceeded 40
mg/d6 and daily after brain abnormality had been detected by
T2-weighted MRI.
MRI Evaluations
Rats were anesthetized with 2% isoflurane in 70% N2/30% O2, fixed
on the animal holder by a rod beneath the teeth, and placed into the
Figure 1. Body weight (a) and blood pressure (b), as a function
of the duration of dietary treatment (JPD), for WKY, SHR, and
SHRSP. Data are expressed as group-averaged mean6SD.
*P,0.05, **P,0.001 vs WKY.
Statistical Parameters for Protein Concentration vs Time From Stroke Curves in
Figure 6
Protein Fluid Curve Correlation Coefficient P
Tf Serum Second order 0.509 ,0.0029
Tf Urine First order 0.806 ,0.0001
a1MAP Serum First order 0.669 ,0.0001
a1MAP Urine First order 0.669 ,0.0001
KBP1a2HS Serum Second order 0.454 ,0.0012
KBP1a2HS Urine First order 0.708 ,0.0001
Gc Serum First order 0.558 ,0.0001
Gc Urine First order 0.789 ,0.0001
a1AT1SPI3 Serum First order 0.417 ,0.006
a1AT1SPI3 Urine First order 0.740 ,0.0001
ApoAIV Serum No correlation
ApoAIV Urine First order 0.812 ,0.0001
CRP Serum Second order 0.469 ,0.004
TTR Serum No correlation
TTR Urine First order 0.728 ,0.0001
Abbreviations are as defined in Figure 6.
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magnet (4.7 T, vertical 15-cm bore) of a Bruker spectrometer
(AMX3 with microimaging accessory). A 6.4-cm-diameter birdcage
coil was used for imaging. After a 3-orthogonal plane gradient echo
scout, a T2 multislice image was obtained. Sixteen contiguous
1-mm-thick slices were analyzed caudal to the olfactory bulb; field
of view was 434 cm2. Turbo spin-echo sequence was used with 16
echoes per excitation, 10 ms interecho time, 85 ms equivalent echo
time, and 4 seconds repetition time. The images were 1283128
points (zero filled to 2563256); 8 images were averaged in 8
minutes and 30 seconds. The occurrence of lesions was identified
with presence of areas of high signal intensity on T2-weighted MRI.
The extension of the lesions was determined by thresholding the
images and interactively drawing outlines of the lesion and of the
whole brain; the ratio between the number of pixels in the lesion
versus that in the whole brain in each slice gave the percentage of the
brain affected by the lesion. The percentage of hyperintense pixels
was evaluated in 9 slices: 4 caudal and 4 rostral to the central slice
where the primary lesion had been detected.
Histology
After the last MRI session, the anesthetized rats were perfused
through the left ventricle with 4% paraformaldehyde in 0.1 mmol/L
phosphate buffer. The brains were dissected, postfixed overnight in
the same solution, cryoprotected by immersion in 30% sucrose-
phosphate buffer, and sectioned with a cryotome. Coronal sections,
10 mm thick, were stained with hematoxylin-eosin and/or toluidine
blue and examined microscopically.
Electrophoretic Techniques
One-dimensional electrophoresis was mainly used to assess the
relative concentrations of the major components (transferrin and
albumin in serum, a-2u-globulin in urine), and 2-dimensional
electrophoresis was mainly used to evaluate with high sensitivity the
average- and low-abundance components under conditions in which
the signal for albumin was saturated.
One-dimensional electrophoresis was run in the presence of SDS,
without sample reduction, in a discontinuous buffer system16 on
polyacrylamide gradients 4% to 20% T. The sample load was 3.75
mg of urine proteins and 0.125 mL of serum per lane. Two-
dimensional electrophoresis maps were obtained by the immobilized
pH gradient (IPG)–Dalt method.17 Sample proteins, reduced with 2%
2-mercaptoethanol, were first resolved according to charge on a
nonlinear pH 4 to 10 IPG18 in the presence of 8 mol/L urea and 0.5%
carrier ampholytes, with an anode-to-cathode distance of 8 cm. The
focused proteins were then fractionated according to size by SDS-
PAGE on 7.5% to 17.5% polyacrylamide gradients, with 2 IPG strips
mounted on each 1603140-mm2 SDS slab. Sample loads were 100
mg of urine proteins or 2 mL of serum. Proteins were stained with
0.3% wt/vol Coomassie or with silver nitrate19 for some urine
samples.
The protein patterns were scanned with a video camera under the
control of NIH Image, release 1.61, and analyzed with the software
PDQUEST version 5.1 (PDI).20 Data for individual proteins (spots or
spot chains identified by immunological or physicochemical
means9–11) are reported as spot volumes as a function of time before
or after MRI evidence of stroke.
Statistical Analysis
Linear and nonlinear fits were taken as statistically significant for
P,0.05. For every fit, R and P values are listed in the Table.
Differences between groups were evaluated by ANOVA for repeated
measurements, followed by Bonferroni’s post hoc test. For SHRSP
this analysis was limited to day 42 from the start of the treatment, the
last time point at which all these rats still survived.
Results
Physical Parameters
The growth of SHRSP was slower than that of SHR and
WKY. Between days 28 and 49 of treatment, SHRSP lost
10% of body mass and weighed 55% to 65% of the age-
matched controls at the time of euthanasia (Figure 1a).
At baseline, WKY, SHR, and SHRSP had systolic blood
pressure of 11865, 120610, and 13068 mm Hg, respec-
tively. Systolic blood pressure of SHR and SHRSP, but not of
WKY, increased markedly during JPD and salt loading
(Figure 1b).
Identification of Brain Damage by MRI and
Histological Analysis
As a result of salt loading, all SHRSP developed cerebral
lesions, at a median of 4263 days from the start of treatment.
Brain lesions occurred within the gray matter, usually in the
frontal or forelimb areas of cortex or in the ventral region of
Figure 2. a, Typical T2-weighted MR images (pixel
resolution, 0.3130.31 mm2; slice thickness, 1 mm)
showing comparable coronal slices (bregma 0.48)
from a single SHRSP, at days 0 and 13 from the
appearance of brain lesions. The arrow points to
the site of the first lesion diagnosed by MRI. b,
Toluidine blue staining of histological brain sec-
tions. In the section from the hyperintense brain
area (bottom), a loss of neuronal cells is evident in
comparison with the unaffected contralateral hemi-
sphere (top). Magnification 340.
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the caudate putamen (Figure 2a). From these single foci the
lesions then spread throughout the brain. In 3 of 8 rats the
damage reached the contralateral hemisphere via the corpus
callosum (not shown). Three days after the first evidence of
brain damage, the extent of the lesion averaged 12.561.6%
(SD; n58).
Histological evaluation confirmed that the alterations in
brain MRI identified areas characterized by tissue thinning
due to loss of neuronal cells (Figure 2b). Neither SHR nor
WKY developed brain abnormalities detectable with MRI or
histological examination throughout the experimental period
(not shown).
Proteomics Data
Urine
Between days 0 and 7 of salt loading, protein loss per day
(24-hour proteinuria) increased 3- to 4-fold in all experimen-
tal groups, but thereafter it changed little for WKY and SHR
(Figure 3a). In SHRSP, mean protein loss increased sharply
(and linearly) after day 28 of treatment (Figure 3). The delay
between the time when proteinuria (evaluated once a week)
indicated a protein loss $40 mg/d6 and the time when MRI,
performed twice a week, identified focal cerebral ischemia
was 963 days. In 6 of 8 rats, urine protein loss peaked
immediately before stroke and declined thereafter.
In SHRSP, not only the total amount of protein in urine but
also the qualitative protein composition changed with time, as
shown by 1-dimensional electrophoretic analysis through
SDS-PAGE (Figure 4). The ratio between 20-kDa compo-
nents, ie, a-2u-globulin, and 65- to 68-kDa components,
mostly albumin, dropped between days 28 and 35 of treat-
ment from approximately 15 (typical for WKY) to approxi-
mately 0 (Figure 4a). The largest protein found in SHRSP
urine was transferrin (molecular weight [Mr], 77 kDa). The
ratio of transferrin to 65- to 68-kDa components in urine
increased from 0 (typical of WKY) to approximately 0.2,
with most of these changes occurring between days 28 and 35
of treatment. After day 35, both ratios in SHRSP differed
significantly from those in WKY (and SHR; not shown). The
ratio between 77-kDa and 65- to 68-kDa proteins in the serum
of rats did not change during the study period (Figure 4b). At
day 42, this ratio in urine of SHRSP had approximated that in
serum (0.1860.03) (Figure 4b and 4c) and had even sur-
Figure 3. Proteinuria as a function of the duration of dietary
treatment (JPD) for WKY, SHR, and SHRSP (as group-averaged
mean6SD) (a) and as a function of time from stroke for individ-
ual SHRSP (b). *P,0.05 vs WKY.
Figure 4. Ratio between amount of proteins of different Mr in serum (sWKY, sSHRSP) and in urine (uWKY, uSHRSP). a, 20 kDa/65 to
68 kDa in urine; b, 77 kDa/65 to 68 kDa in serum; c, 77 kDa/65 to 68 kDa in urine. Data are from 1-dimensional electrophoresis (1-DE)
run under nonreducing conditions on aliquots of serum (0.125 mL) and of urine proteins (3.75 mg) on 4% to 20% T SDS-PAGE gels.
*P,0.05 vs WKY.
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passed it (0.2060.02), so that the bulky proteins were now
leaking freely into the urine.
Analysis of the protein pattern in urine by 2-dimensional
electrophoresis (Figure 5) confirmed that a-2u-globulin is by
far the major protein in male rat urine under baseline
conditions. Albumin and IgL were the only serum proteins
recognized in the pattern of WKY and SHR at all time
points,21–23 whereas in SHRSP the proteins of high Mr lost in
urine during treatment were resolved by 2-dimensional elec-
trophoretic analysis as transferrin, albumin, thiostatin,
kallikrein-binding protein, a2-HS-glycoprotein, serine pro-
tease inhibitor 3, a1-antitrypsin, Gc-globulin, apolipoprotein
A-IV, transthyretin, and the albumin fragments migrating as
slanted rows with Mr 50 and 30 kDa. Hemopexin is not easily
recognized in Coomassie-stained patterns, but its presence
was confirmed by immunoblotting (not shown).
Figure 6 shows the best-fit curves for individual SHRSP
data of the amounts of major proteins in urine and plasma
versus time from stroke. For every protein detected in urine,
a positive and highly significant linear correlation (R$0.67,
P,0.0001) was observed with time (Table). The intercept of
the regression line on the time axis was approximately day
220 from stroke for most proteins in urine but corresponded
to 217 for thiostatin (versus 230 for its first appearance in
serum) and to 225 for transthyretin.
An extensive preliminary investigation of which gels were
heavily loaded and silver-stained for high sensitivity detected
no difference in the amounts of minor components among
urine from WKY, SHR, and SHRSP until loss of serum
proteins began in the latter (not shown).
Serum
The 2-dimensional electrophoretic patterns of WKY and
SHRSP sera after weeks of salt loading are shown in Figure
5. Several qualitative and quantitative differences were ob-
served, most notably the appearance of thiostatin and serine
protease inhibitor 3 and the drastic decrease of a2-HS-glyco-
protein, transferrin, and albumin. The long-term course for
major proteins is plotted in Figure 6 as a function of time
from stroke. For 5 proteins (apolipoprotein A-IV, transthyre-
tin, apolipoprotein E, retinol-binding protein, a1-inhibitor III;
not shown) no definite trend was detected; the increase in
group-specific component levels over time was very low. The
concentrations of thiostatin and a1-antitrypsin1serine pro-
tease inhibitor 3 increased linearly with time; those of
transferrin, kallikrein-binding protein1a2-HS-glycoprotein,
haptoglobin, and C-reactive protein varied according to a
second-order curve, with maximal values in all cases at
approximately day 220 before stroke.
Discussion
In the present report we describe the occurrence of inflam-
matory markers in urine and plasma in an experimental
model, SHRSP, that develops brain damage invariably pre-
ceded by massive proteinuria.
Before the occurrence of ischemic damage, the serum
protein pattern of SHRSP resembles that of experimental
inflammation.10–13 Specifically, a1-antitrypsin1serine pro-
tease inhibitor 3 and thiostatin increase linearly in serum
throughout the duration of the treatment. Kallikrein-binding
protein1a2-HS-glycoprotein increase at first, then decrease,
with a2-HS-glycoprotein, a negative acute-phase protein,
almost vanishing at the latest experimental times (Figure 5).
In humans, C-reactive protein is the most sensitive marker
of many inflammatory conditions, since its level increases by
1 order of magnitude within a few hours from the noxious
stimulus,24 and several studies have identified C-reactive
protein as a strong predictor of myocardial infarction25,26 and
stroke.27 It should be noted, however, that the set of proteins
affected in acute-phase reactions differs depending on the
species.28,29 In the rat, C-reactive protein levels are only
marginally affected during early inflammation; serum amy-
loid A is lacking altogether from rat serum. On the contrary,
in the rat a dramatic rise in thiostatin (also called a1-major
acute-phase protein), a species-specific thiol protease inhibi-
tor,30,31 as well as an increase in a2-macroglobulin are
observed during inflammation. In SHRSP most of the acute-
Figure 5. Two-dimensional electrophoresis (2-DE) maps of
serum (left) and urine (right), from a control WKY (top) and a
poststroke SHRSP (bottom). All samples were collected at day
49 from the beginning of the dietary treatment, corresponding to
day 13 from stroke for SHRSP (rat 3; refer to Figure 3b). Serum
is loaded on a volume basis (2 mL) and proteins on a weight
basis (100 mg). a1AT indicates a1-antitrypsin; a1I3, a1-inhibitor III;
a1M, a1-macroglobulin; a1MAP, a1-major acute-phase protein,
or thiostatin; a2HS, a2-HS-glycoprotein; apo, apolipoprotein; Cp,
ceruloplasmin; CRP, C-reactive protein; Gc, Gc-globulin; Hp,
haptoglobin; KBP, kallikrein-binding protein; MUP, a-2u-
globulin, or major urinary protein; SA, albumin; SPI3, serine pro-
tease inhibitor-3; Tf, transferrin; TTR, transthyretin; and pI, iso-
electric point.
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phase proteins begin to increase over basal levels soon after
the start of the treatment (Figure 6); thiostatin is first detected
at least 4 weeks before the occurrence of stroke.
Most of the acute-phase proteins found in serum are also
detected in urine of SHRSP, and their level increases over
time, with maximal values at the date of euthanasia (Figure
6). A time delay with respect to serum that varies from one
protein to another is observed. In particular, transthyretin (Mr,
56 kDa) is detected in urine approximately 25 days before the
appearance of ischemic brain features; thiostatin is detected
only 16 days before. Thus, selectivity of excretion in terms of
both size and charge is noticed. Indeed, the higher 77 kDa/65
to 68 kDa ratio measured in urine than in serum (Figure 4) is
due to preferential loss of albumin versus other components
of similar Mr (Figure 5). In addition, in urine samples from
SHRSP only the most alkaline isoforms (glycoforms) of
transferrin are observed (Figure 5). a-2u-Globulin32 is a
pheromone-binding lipocalin synthesized in male rat liver
under the influence of androgens and readily lost in urine. Its
excretion is known to be reduced in animals on a low-protein
diet.33 After 42 days of treatment, SHRSP excrete ,7 mg/d
a-2u-globulin versus 12 mg/d for both WKY and SHR.
An increase in proteinuria before the occurrence of stroke
in susceptible animals (SHRSP) subjected to high sodium
intake has been previously reported.6 No information, how-
ever, was available on the protein composition of urine of
SHRSP compared with WKY or SHR. Our data detail which
proteins are lost in urine, as well as the time course of their
excretion, in relationship to their varying concentration in
serum.
The changes in the serum levels of several acute-phase
proteins, with some of the positive acute-phase proteins being
eventually excreted in urine, point to an inflammatory con-
dition developing before stroke. In the present investigation
we have not collected evidence on the tissues where the
inflammatory status first develops in SHRSP. Data in the
literature report extensive kidney abnormalities in this animal
model, including thrombotic, proliferative, and necrotic le-
sions in arterioles and glomeruli,34–36 often preceding the
occurrence of stroke.1,37,38 In addition, for patients with
end-stage renal disease, a complex and mutual interaction
between acute-phase inflammatory process and all aspects of
kidney disease (uremia, heart failure, malnutrition, anemia)
has been proposed.39 Since subpopulations of individuals
with high levels of C-reactive protein and cytokines have
been reported among patients both with normal renal function
and with chronic renal failure, no conclusion is possible about
cause versus consequence.39 Definitely, genetic background
Figure 6. Concentration as a function of time from stroke for major proteins in serum and urine of SHRSP. A curve representing the
best linear or nonlinear fits is superimposed to the scatter of individual data. The sequence of the panels is according to isoelectric
point (pI)/Mr. The statistical parameters are listed in the Table. 2-DE indicates 2-dimensional electrophoresis.
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plays a relevant role in SHRSP because neither organ failure
nor acute-phase reaction is observed in the related rat strain
SHR under identical environment conditions.
Treatment with angiotensin I–converting enzyme inhibi-
tors and angiotensin II antagonists prevents renal disorders,
including proteinuria, as well as the occurrence of brain
lesions.40–43 The protective effects of these drugs, however,
are independent of alterations in blood pressure, which
supports the hypothesis that development of vascular injury
requires the concurrent involvement of local factors. In this
experimental model the same drugs also exert protective
effects against cerebral ischemia, which in turn suggests a
potential role in the control of vascular permeability as well
as of the development of an inflammatory reaction.
An increasing number of in vivo data suggest that the
inflammatory response that follows stroke is involved in the
pathogenesis of cerebral ischemia.44 Cytokines, synthesized
locally during the development of brain lesions, have been
suggested to exacerbate brain ischemic injury by several
mechanisms; they activate the synthesis of acute-phase reac-
tants.45 Less is known about the prognostic value of inflam-
matory markers in this pathological condition. C-reactive
protein levels, however, have been reported to be an inde-
pendent predictor not only of cardiovascular events but also
of ischemic brain disease.26,46 Moreover, C-reactive protein
concentration within 72 hours of an ischemic stroke is either
an independent predictor of survival27 or an irrelevant param-
eter.47 Thus, an inflammatory reaction may also have a
pathogenetic role in the occurrence of acute stroke. Experi-
mental models to test this hypothesis, however, are lacking.
SHRSP exposed to JPD, in which inflammation develops
before the appearance of anomalous features in brain MRI,
represent a useful experimental tool to understand how
inflammation contributes to ischemic brain injury and to
answer the question of whether anti-inflammatory strategies
may affect genesis, progression, and outcome of brain dam-
age. On the basis of this growing understanding, new phar-
macological approaches should be designed that will enlarge
our therapeutic armamentarium for the prevention and/or
treatment of brain disease.
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